Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Total neoadjuvant oxaliplatin-based therapy (TNT) before (induction) and after (consolidation) chemoradiation for advanced rectal cancer: MRI correlation on complete response and outcome.
Presenter
Kok Hoe Chan
The University of Texas Health Science Center at Houston (UTHealth Houston) McGovern Medical School
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 165)
DOI
10.1200/JCO.2023.41.4_suppl.165
Abstract #
165
Poster Bd #
J5
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2023 ASCO Annual Meeting
Organ preservation and total neoadjuvant therapy for rectal cancer: Investigating long course chemoradiation versus short course radiation therapy.
Speaker: Paul Bernard Romesser, MD
Videos & Slides
2023 ASCO Gastrointestinal Cancers Symposium
Organ preservation and total neoadjuvant therapy for rectal cancer: Investigating long-course chemoradiation versus short-course radiation therapy.
Speaker: Byung Kwan Park, MD
Speaker: To Be Determined
Videos & Slides
2024 ASCO Annual Meeting
Ramucirumab plus paclitaxel as switch maintenance versus continuation of oxaliplatin-based chemotherapy in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancer: The ARMANI phase III trial.
Speaker: Filippo Pietrantonio, MD